News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

Tuesday, 10. December 2019

Category

Publications

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.

Published

Tuesday, 10. September 2019

Category

Partner News

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis

Published

Wednesday, 14. August 2019

Category

Publications

Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.

Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.

Published

Thursday, 25. July 2019

Category

Partner News

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma

Published

Wednesday, 22. May 2019

Category

Publications

Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.

Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team